

BIOCRYST PHARMACEUTICALS INC

Form 8-K

July 24, 2007



**Item 5.03 Amendments to Articles of Incorporation:**

On July 18, 2007 BioCryst Pharmaceuticals, Inc. filed a Certificate of Amendment to the Third Restated Certificate of Incorporation. This amendment was approved by the stockholders at the Annual Meeting held on May 16, 2007 and amends the first paragraph of Article FOURTH as follows:

FOURTH. The total number of shares of all classes of stock which the Corporation shall have authority to issue is One Hundred Million (100,000,000) shares consisting of (i) Ninety-Five Million (95,000,000) shares of Common Stock, \$0.01 par value per share ( Common Stock ), and (ii) Five Million (5,000,000) shares of Preferred Stock, \$0.01 par value per share ( Preferred Stock ), of which Forty-Five Thousand (45,000) shares are designated Series B Junior Participating Preferred Stock.

The Third Restated Certificate of Incorporation previously authorized Fifty Million (50,000,000) shares consisting of (i) Forty-Five Million shares of Common Stock, \$0.01 par value per share ( Common Stock ), and (ii) Five Million (5,000,000) shares of Preferred Stock, \$0.01 par value per share ( Preferred Stock ), of which Forty-Five Thousand (45,000) shares are designated Series B Junior Participating Preferred Stock.

**Item 9.01. Financial Statements and Exhibits:**

<b>Exhibit No.</b>	<b>Description</b>
3.1	Certificate of Amendment to the Third Restated Certificate of Incorporation of BioCryst Pharmaceuticals, Inc.

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Dated: July 24, 2007

**BioCryst Pharmaceuticals, Inc.**

By: /s/ Michael A. Darwin  
Michael A. Darwin  
Chief Financial Officer and  
Chief Accounting Officer

**EXHIBIT INDEX**

<b>Exhibit No.</b>	<b>Description</b>
3.1	Certificate of Amendment to the Third Restated Certificate of Incorporation of BioCryst Pharmaceuticals, Inc.